BR112017024253A2 - métodos de tratamento de inflamação ou dor neuropática. - Google Patents

métodos de tratamento de inflamação ou dor neuropática.

Info

Publication number
BR112017024253A2
BR112017024253A2 BR112017024253A BR112017024253A BR112017024253A2 BR 112017024253 A2 BR112017024253 A2 BR 112017024253A2 BR 112017024253 A BR112017024253 A BR 112017024253A BR 112017024253 A BR112017024253 A BR 112017024253A BR 112017024253 A2 BR112017024253 A2 BR 112017024253A2
Authority
BR
Brazil
Prior art keywords
methods
neuropathic pain
treating inflammation
inflammation
treating
Prior art date
Application number
BR112017024253A
Other languages
English (en)
Inventor
Wayne Thurston Archie Jr
Rodney Beals Channing
A Grice Cheryl
paul o'neill Gary
peter fraser Iain
Lorayne BLANKMAN Jacqueline
Robert CLAPPER Jason
Alan B Ezekowitz R
K Jones Todd
Original Assignee
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc
Publication of BR112017024253A2 publication Critical patent/BR112017024253A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017024253A 2015-05-11 2016-05-10 métodos de tratamento de inflamação ou dor neuropática. BR112017024253A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562159770P 2015-05-11 2015-05-11
US201662297670P 2016-02-19 2016-02-19
PCT/US2016/031668 WO2016183097A1 (en) 2015-05-11 2016-05-10 Methods of treating inflammation or neuropathic pain

Publications (1)

Publication Number Publication Date
BR112017024253A2 true BR112017024253A2 (pt) 2018-07-24

Family

ID=57249499

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017024253A BR112017024253A2 (pt) 2015-05-11 2016-05-10 métodos de tratamento de inflamação ou dor neuropática.

Country Status (14)

Country Link
US (3) US10450302B2 (pt)
EP (1) EP3294731A4 (pt)
JP (2) JP2018515460A (pt)
KR (1) KR20180004263A (pt)
CN (2) CN113413387A (pt)
AU (3) AU2016262459A1 (pt)
BR (1) BR112017024253A2 (pt)
CA (1) CA2984480A1 (pt)
EA (1) EA201792496A1 (pt)
HK (1) HK1252658A1 (pt)
IL (2) IL255239A0 (pt)
MX (2) MX2017014344A (pt)
SG (1) SG10202012002TA (pt)
WO (1) WO2016183097A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101653473B1 (ko) 2012-01-06 2016-09-01 어바이드 테라퓨틱스, 인크. 카르바메이트 화합물 및 그의 제조 및 이용 방법
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
WO2016183097A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190108B1 (ar) 2016-11-16 2023-09-17 H Lundbeck As تركيبات صيدلانية
MA46866B1 (fr) * 2016-11-16 2021-11-30 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
AU2021259496A1 (en) 2020-04-21 2022-11-10 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
US20210369704A1 (en) * 2020-05-29 2021-12-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for preventing and treating headache through enhancing 2-arachydonyl glyerol activity
WO2023192981A1 (en) * 2022-03-31 2023-10-05 Mayo Foundation For Medical Education And Research Methods and materials for treating pancreatic diseases and disorders

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (pt) 1967-10-17 1970-06-01
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
WO1989011794A1 (en) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Plant growth inhibitor
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
CA2122479C (en) 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
WO1993011097A1 (en) 1991-11-27 1993-06-10 E.I. Du Pont De Nemours And Company Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
CA2147283C (en) 1992-10-16 2007-01-16 Kouichi Nakamichi Method of manufacturing wax matrices
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH09506920A (ja) 1993-12-22 1997-07-08 シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー カルバメートの製造法
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
JP2000500448A (ja) 1995-11-15 2000-01-18 ゼネカ リミテッド 除草性置換ピラゾール化合物
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2003511045A (ja) 1999-10-04 2003-03-25 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー Ｒｎａ結合化合物の同定方法
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ATE420644T1 (de) * 2002-02-20 2009-01-15 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (en) 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Process for preparing carbamates
BRPI0507499A (pt) 2004-02-18 2007-07-24 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5
JP2008521768A (ja) 2004-12-23 2008-06-26 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用
KR101405545B1 (ko) 2005-11-28 2014-07-03 마리누스 파마슈티컬스 ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
AR064491A1 (es) 2006-12-22 2009-04-08 Astex Therapeutics Ltd Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
FR2938341A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
CA2730610A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and their use as gpcr modulators
US8772318B2 (en) 2008-11-14 2014-07-08 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
KR20110131302A (ko) 2009-03-23 2011-12-06 엠에스디 가부시키가이샤 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
BR112012010471B1 (pt) 2009-11-03 2020-10-20 Bayer Materialscience Ag formulação de fotopolímero compreendendo fluorouretanos e processo para exposição de mídia holográfica
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
KR101653473B1 (ko) * 2012-01-06 2016-09-01 어바이드 테라퓨틱스, 인크. 카르바메이트 화합물 및 그의 제조 및 이용 방법
SG10201602862RA (en) 2012-01-06 2016-05-30 Agios Pharmaceuticals Inc Therapeutically Active Compounds And Their Methods Of Use
MX2014011134A (es) * 2012-03-19 2014-12-10 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos.
EP2844247A4 (en) * 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
MX368353B (es) 2012-11-02 2019-09-30 Vertex Pharma Composiciones farmaceuticas para el tratamiento de enfermedades mediadas por cftr.
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
US10093630B2 (en) 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016183097A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190108B1 (ar) 2016-11-16 2023-09-17 H Lundbeck As تركيبات صيدلانية
MA46866B1 (fr) 2016-11-16 2021-11-30 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Also Published As

Publication number Publication date
IL284299A (en) 2021-07-29
IL255239A0 (en) 2017-12-31
US20200055841A1 (en) 2020-02-20
EP3294731A4 (en) 2018-10-24
AU2022203543A1 (en) 2022-06-16
JP2022008597A (ja) 2022-01-13
EP3294731A1 (en) 2018-03-21
WO2016183097A1 (en) 2016-11-17
SG10202012002TA (en) 2021-01-28
US20210230145A1 (en) 2021-07-29
JP2018515460A (ja) 2018-06-14
CN113413387A (zh) 2021-09-21
US20180099951A1 (en) 2018-04-12
MX2017014344A (es) 2018-04-11
CA2984480A1 (en) 2016-11-17
MX2021014815A (es) 2022-01-18
AU2020213382A1 (en) 2020-08-27
AU2016262459A1 (en) 2017-12-21
US10450302B2 (en) 2019-10-22
KR20180004263A (ko) 2018-01-10
HK1252658A1 (zh) 2019-05-31
EA201792496A1 (ru) 2018-04-30
US11034674B2 (en) 2021-06-15
CN107849021A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
BR112017024253A2 (pt) métodos de tratamento de inflamação ou dor neuropática.
EP3384050A4 (en) MONITORING THE TREATMENT OR PROGRESSION OF MYELOMA
BR112017018413A2 (pt) tratamento de pancreatite
BR112017017582A2 (pt) sistema de tratamento oral
FI20155065A (fi) Monikäyttölaite eläimen hoitoon
DK3231444T3 (da) Ny behandling
SG11201702688UA (en) Methods of treating rsv infections
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3393579T3 (da) Øjenbehandlingssystem
BR112016022976A2 (pt) Métodos para o tratamento de hcv
HK1249865B (zh) 疼痛的治療
BR112018000204A2 (pt) métodos de tratamento de colite
BR112016015712A8 (pt) método de tratamento de doenças hepáticas.
BR112016015641A8 (pt) composições e métodos de tratamento de condições patológicas inflamatórias da pele usando alantoína.
DK3302478T3 (da) Pac-1 kombinations behandling
TWI800561B (zh) 毛髮處理方法
DK3580182T3 (da) Vandbehandling
FI20150362A (fi) Järjestelmä huippukylmähoitoon
BR112017000359A2 (pt) combinação de pregabalina e meloxicam para o tratamento de dor neuropática
PL3220952T3 (pl) Sposób leczenia lub zapobiegania udarowi
DK3518801T3 (da) System til kirurgisk behandling
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3364975T3 (da) Kombination af trazodon og gabapentin til behandling af smerter
DK3229830T3 (da) Metoder til behandling og forudsigelse af non-hæmatopoietisk maligne tumorer
FR3035458B1 (fr) Capuchon de fixation rotule

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25D Requested change of name of applicant approved

Owner name: LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: H. LUNDBECK A/S (DK)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 403/10 , C07D 213/55 , C07D 295/192 , C07D 295/205 , C07D 403/00

Ipc: C07D 295/205 (2006.01), C07D 213/55 (2006.01), C07

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]